摘要
目的观察拉贝洛尔联合维生素D滴剂治疗子痫前期(PE)患者的临床效果。方法对100例PE患者的临床资料进行分析,根据用药方案不同分为对照组与研究组,各50例。对照组给予拉贝洛尔片治疗,研究组给予拉贝洛尔片联合维生素D滴剂治疗。比较两组治疗前及治疗第14天的收缩压、舒张压、24 h尿蛋白定量水平,不良反应发生情况。结果对照组治疗前收缩压水平与研究组比较,差异无统计学意义(P>0.05);治疗第14天,两组收缩压水平均低于本组治疗前,且研究组收缩压(131.56±1.05)mm Hg(1 mm Hg=0.133 kPa)低于对照组的(139.26±0.92)mm Hg,差异有统计学意义(P<0.05)。对照组治疗前舒张压水平与研究组比较,差异无统计学意义(P>0.05);治疗第14天,两组舒张压水平均低于本组治疗前,且研究组舒张压(81.84±1.79)mm Hg低于对照组的(92.62±1.81)mm Hg,差异有统计学意义(P<0.05)。对照组治疗前24 h尿蛋白定量水平与研究组比较,差异无统计学意义(P>0.05);治疗第14天,两组24 h尿蛋白定量水平均低于本组治疗前,且研究组24 h尿蛋白定量(0.30±0.02)g/24 h低于对照组的(0.58±0.01)g/24 h,差异有统计学意义(P<0.05)。治疗期间,研究组发生鼻塞2例,乏力1例,不良反应总发生率为6.00%(3/50)。对照组发生皮肤刺痛1例,恶心2例,头晕1例,不良反应总发生率为8.00%(4/50)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论拉贝洛尔联合维生素D滴剂治疗PE患者的临床疗效肯定,在有效控制患者血压的同时,能降低患者24 h尿蛋白定量水平,且不会增加不良反应。
Objective To observe the clinical effect of labetalol combined with vitamin D drops in the treatment of patients with preeclampsia(PE).Methods The clinical data of 100 PE patients were analyzed,and they were divided into control group and study group,each with 50 cases.The control group was treated with labetalol tablets,and the study group was treated with labetalol tablets combined with vitamin D drops.Comparison of systolic blood pressure,diastolic blood pressure,24 h urinary protein quantification level before treatment and on the 14th day of treatment,and the occurrence of adverse reactions between the two groups.Results Before treatment,there was no significant difference in the level of systolic blood pressure between the control group and the study group(P>0.05).On the 14th day of treatment,the systolic blood pressure in both groups was lower than that before treatment;the systolic blood pressure in the study group was(131.56±1.05)mm Hg(1 mm Hg=0.133 kPa),which was lower than(139.26±0.92)mm Hg in the control group;the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in diastolic blood pressure between the control group and the study group(P>0.05).On the 14th day of treatment,the diastolic blood pressure in both groups was lower than that before treatment;the diastolic blood pressure in the study group was(81.84±1.79)mm Hg,which was lower than(92.62±1.81)mm Hg in the control group;the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in 24 h urinary protein quantification between the control group and the study group(P>0.05).On the 14th day of treatment,the 24 h urinary protein quantification in both groups was lower than that before treatment in this group;the 24 h urinary protein quantification in the study group was(0.30±0.02)g/24 h,which was lower than(0.58±0.01)g/24 h in the control group;the difference was statistically significant(P<0.05).During treatment,2 cases of nasal congestion and 1 case of malaise occurred in the study group,and the total incidence of adverse reactions was 6.00%(3/50);in the control group,1 case of skin tingling,2 cases of nausea and 1 case of dizziness occurred,and the total incidence of adverse reactions was 8.00%(4/50).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The clinical efficacy of the combination of labetalol and vitamin D drops in the treatment of preeclampsia patients is definite.It can reduce 24 h urinary protein quantification without increasing the adverse reactions while effectively controlling the patients'blood pressure.
作者
赵苏
相李平
ZHAO Su;XIANG Li-ping(Linyi Central Hospital,Linyi 276400,China)
出处
《中国现代药物应用》
2025年第10期7-11,共5页
Chinese Journal of Modern Drug Application
